Plasma osteoprotegerin levels increase with the severity of cerebral artery atherosclerosis

Clinical Biochemistry

Volumn 46, Issue 12, 2013, Pages 1036-1040

  Kim, Jinkwon ^a,b   Song, Tae Jin ^a   Yang, Seung Hee ^a   Lee, Ok Hee ^a   Nam, Hyo Suk ^a   Kim, Young Dae ^a   Kim, Eun Hee ^a   Lee, Hye Sun ^a   Nam, Chung Mo ^a   Heo, Ji Hoe ^a  

^a Yonsei University College of Medicine   (South Korea)

^b CHA University   (South Korea)

Author keywords

Atherosclerosis; Cerebral artery; Cerebral infarction; Osteoprotegerin; Stroke; Tumor necrosis factor

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; OSTEOPROTEGERIN;

ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BRAIN ARTERY; BRAIN ATHEROSCLEROSIS; BRAIN INFARCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

ATHEROSCLEROSIS; CEREBRAL ARTERY; CEREBRAL INFARCTION; CI; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTED TOMOGRAPHY; CONFIDENCE INTERVAL; CT; CTA; DIGITAL SUBTRACTION ANGIOGRAPHY; DSA; EGFR; ESTIMATED GLOMERULAR FILTRATION RATE; HIGH SENSITIVE C-REACTIVE PROTEIN; HS-CRP; INTERQUARTILE RANGE; IQR; MAGNETIC RESONANCE; MAGNETIC RESONANCE ANGIOGRAPHY; MATRIX METALLOPROTEINASES; MMP; MR; MRA; ODDS RATIO; OPG; OR; OSTEOPROTEGERIN; RANKL; RECEPTOR ACTIVATOR OF NUCLEUS FACTOR-ΚB LIGAND; SD; STANDARD DEVIATION; STROKE; TNF; TRAIL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND;

ATHEROSCLEROSIS; CEREBRAL ARTERIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84880508962     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.05.048     Document Type: Article

References (24)

1. Kiechl S., Werner P., Knoflach M., Furtner M., Willeit J., Schett G. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006, 4:801-811.
2. Karatolios K., Pankuweit S., Goettsch C., Hofbauer L.C., Timmesfeld N., Al-Fakhri N., et al. Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (trail) levels in malignant and benign pericardial effusions. Clin Biochem 2012, 45:237-242.
3. Lieb W., Gona P., Larson M.G., Massaro J.M., Lipinska I., Keaney J.F., et al. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 2010, 30:1849-1854.
4. Stepien E., Wypasek E., Stopyra K., Konieczynska M., Przybylo M., Pasowicz M. Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals. Clin Biochem 2011, 44:826-831.
5. Van Campenhout A., Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009, 204:321-329.
6. Stepien E., Fedak D., Klimeczek P., Wilkosz T., Banys R.P., Starzyk K., et al. Osteoprotegerin, but not osteopontin, as a potential predictor of vascular calcification in normotensive subjects. Hypertens Res 2012, 35:531-538.
7. Candido R., Toffoli B., Corallini F., Bernardi S., Zella D., Voltan R., et al. Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J Vasc Res 2010, 47:252-261.
8. Browner W.S., Lui L.Y., Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001, 86:631-637.
9. Ali Z., Ellington A.A., Mosley T.H., Kullo I.J. Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites. Atherosclerosis 2009, 206:575-580.
10. Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002, 106:1192-1194.
11. Abedin M., Omland T., Ueland T., Khera A., Aukrust P., Murphy S.A., et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007, 99:513-518.
12. Jensen J.K., Ueland T., Atar D., Gullestad L., Mickley H., Aukrust P., et al. Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. J Intern Med 2010, 267:410-417.
13. Adams H.P., Bendixen B.H., Kappelle L.J., Biller J., Love B.B., Gordon D.L., et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Toast. Trial of org 10172 in acute stroke treatment. Stroke 1993, 24:35-41.
14. North American Symptomatic Carotid Endarterectomy Trial Collaborators Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991, 325:445-453.
15. Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators Design, progress and challenges of a double-blind trial of warfarin versus aspirin for symptomatic intracranial arterial stenosis. Neuroepidemiology 2003, 22:106-117.
16. National Kidney Foundation K/doqi clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266.
17. Wong K.S., Li H. Long-term mortality and recurrent stroke risk among Chinese stroke patients with predominant intracranial atherosclerosis. Stroke 2003, 34:2361-2366.
18. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109:2175-2180.
19. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors rankl and osteoprotegerin. Circ Res 2004, 95:1046-1057.
20. Doherty T.M., Asotra K., Fitzpatrick L.A., Qiao J.H., Wilkin D.J., Detrano R.C., et al. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci U S A 2003, 100:11201-11206.
21. Caidahl K., Ueland T., Aukrust P. Osteoprotegerin: a biomarker with many faces. Arterioscler Thromb Vasc Biol 2010, 30:1684-1686.
22. Vik A., Mathiesen E.B., Johnsen S.H., Brox J., Wilsgaard T., Njolstad I., et al. Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population - the Tromso study. J Thromb Haemost 2010, 8:898-905.
23. Vik A., Mathiesen E.B., Noto A.T., Sveinbjornsson B., Brox J., Hansen J.B. Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis 2007, 191:128-134.
24. Golledge J., McCann M., Mangan S., Lam A., Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004, 35:1636-1641.